419 documents

Read All
19:31 , Oct 5, 2018 |  BC Week In Review  |  Company News

BARDA, Genentech partner against influenza, health security threats

HHS’s Biomedical Advanced Research and Development Authority and Genentech Inc. partnered to develop products to fight influenza and other health security threats. BARDA initially will provide $43 million over five years to develop baloxavir marboxil...
Read More
21:44 , Oct 4, 2018 |  BC Innovations  |  Emerging Company Profile

Banking on exosomes

Alxerion Biotech LLC is building a biobank of exosomes from diverse species as a comprehensive source for therapeutics discovery. Its initial focus is on cancer. The company aims to collect and screen 350,000 samples from...
Read More
20:36 , Oct 1, 2018 |  BC Extra  |  Company News

BARDA, Genentech partner against influenza, health security threats

HHS’s Biomedical Advanced Research and Development Authority and Genentech Inc. partnered to develop products to fight influenza and other health security threats. BARDA initially will provide $43 million over five years to develop baloxavir marboxil...
Read More
17:33 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Sarcoma; pancreatic cancer In vitro and mouse studies identified an amiloride-based PLAU inhibitor that could help treat metastatic fibrosarcoma and pancreatic cancers. Chemical synthesis and in vitro testing of amiloride analogs in enzyme activity...
Read More
23:05 , Sep 25, 2018 |  BC Extra  |  Preclinical News

Ionis, Rockefeller team find peripheral blood target for Alzheimer's

Ionis Pharmaceutics Inc. (NASDAQ:IONS) and The Rockefeller University found blood plasmin drives Alzheimer's disease progression and immune responses in the brain, shedding light on neuroinflammation's role in AD. The team suggested antisense oligonucleotide depletion of...
Read More
19:27 , Sep 10, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Nanoparticles bound to red blood cells (RBCs) could be used to deliver drugs to the vasculature of specific organs. The method involves mixing bare nanogels with ex vivo RBCs to enable RBC-nanoparticle binding,...
Read More
17:00 , Aug 9, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A biomanufacturing method could enable ex vivo production of human platelets to treat thrombocytopenia and other hematologic indications. In human induced pluripotent stem (iPS) cell-derived megakaryocyte cell lines cultured in shaking flasks,...
Read More
16:10 , Jul 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Stroke Patient sample and mouse studies suggest a factor H-CR2 conjugate that inhibits C3d deposition could help treat stroke. In postmortem brain samples from three patients, deposition of C3d was higher in the perilesional...
Read More
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
Read More
16:16 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

ZZ Biotech's 3K3A-APC reduces hemorrhage rate in Phase II for acute ischemic stroke

ZZ Biotech LLC (Houston, Texas) reported preliminary data from the Phase II RHAPSODY trial in 110 patients with moderate to severe acute ischemic stroke who were treated with IV tissue plasminogen activator (tPA), intra-arterial thrombectomy...
Read More